Summary:
- LEADS Biolabs has received NMPA acceptance for its New Drug Application (NDA) for Opamtistomig, a bispecific antibody targeting PD-L1 and 4-1BB.
- This therapy represents a significant advancement in immuno-oncology, as it is positioned to become the world’s first approved 4-1BB-targeting therapeutic agent.